FOLR1 and ovarian carcinoma: The high levels of FRα in ovarian cancer suggested opportunities for a targeted immunotherapy of EOC employing CAR T. Engineered CAR T cells containing an FRα-specific epitope coupled to the T cell receptor chain CD3ζ induced regression in preclinical models [176].